source
- Four CDMOs to watch as biopharma outsourcing growsThe article lists four contract development and manufacturing organizations (CDMOs) that biopharma companies can partner with as demand for external development and manufacturing rises. Lonza, bas…
- Novo Nordisk abandons two phase 3 trials of ziltivekimab, dimming blockbuster hopesNovo Nordisk announced it is terminating two late‑stage phase 3 studies of its IL‑6 ligand antibody ziltivekimab. The Hermes and Athena trials enrolled about 4,900 and 673 patients with heart fail…